Literature DB >> 26657171

Adolescent methylphenidate treatment differentially alters adult impulsivity and hyperactivity in the Spontaneously Hypertensive Rat model of ADHD.

S S Somkuwar1, K M Kantak2, M T Bardo3, L P Dwoskin4.   

Abstract

Impulsivity and hyperactivity are two facets of attention deficit/hyperactivity disorder (ADHD). Impulsivity is expressed as reduced response inhibition capacity, an executive control mechanism that prevents premature execution of an intermittently reinforced behavior. During methylphenidate treatment, impulsivity and hyperactivity are decreased in adolescents with ADHD, but there is little information concerning levels of impulsivity and hyperactivity in adulthood after adolescent methylphenidate treatment is discontinued. The current study evaluated impulsivity, hyperactivity as well as cocaine sensitization during adulthood after adolescent methylphenidate treatment was discontinued in the Spontaneously Hypertensive Rat (SHR) model of ADHD. Treatments consisted of oral methylphenidate (1.5mg/kg) or water vehicle provided Monday-Friday from postnatal days 28-55. During adulthood, impulsivity was measured in SHR and control strains (Wistar Kyoto and Wistar rats) using differential reinforcement of low rate (DRL) schedules. Locomotor activity and cocaine sensitization were measured using the open-field assay. Adult SHR exhibited decreased efficiency of reinforcement under the DRL30 schedule and greater levels of locomotor activity and cocaine sensitization compared to control strains. Compared to vehicle, methylphenidate treatment during adolescence reduced hyperactivity in adult SHR, maintained the lower efficiency of reinforcement, and increased burst responding under DRL30. Cocaine sensitization was not altered following adolescent methylphenidate in adult SHR. In conclusion, adolescent treatment with methylphenidate followed by discontinuation in adulthood had a positive benefit by reducing hyperactivity in adult SHR rats; however, increased burst responding under DRL compared to SHR given vehicle, i.e., elevated impulsivity, constituted an adverse consequence associated with increased risk for cocaine abuse liability.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Attention deficit/hyperactivity disorder; Differential reinforcement of low rates schedule; Impulsivity; Methylphenidate; Spontaneously Hypertensive Rat

Mesh:

Substances:

Year:  2015        PMID: 26657171      PMCID: PMC4764879          DOI: 10.1016/j.pbb.2015.12.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  112 in total

Review 1.  Development of the motivational system during adolescence, and its sensitivity to disruption by nicotine.

Authors:  Danielle S Counotte; August B Smit; Tommy Pattij; Sabine Spijker
Journal:  Dev Cogn Neurosci       Date:  2011-06-06       Impact factor: 6.464

2.  Differential reinforcement of low rates performance by impulsive and reflective children.

Authors:  N Stein; R Landis
Journal:  J Exp Child Psychol       Date:  1975-02

Review 3.  The neural basis of inhibition in cognitive control.

Authors:  Adam R Aron
Journal:  Neuroscientist       Date:  2007-06       Impact factor: 7.519

Review 4.  Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.

Authors:  L S Goldman; M Genel; R J Bezman; P J Slanetz
Journal:  JAMA       Date:  1998-04-08       Impact factor: 56.272

5.  Strain and sex differences in the locomotor response and behavioral sensitization to cocaine in hyperactive rats.

Authors:  S Cailhol; P Mormède
Journal:  Brain Res       Date:  1999-09-18       Impact factor: 3.252

6.  Cocaine self-administration in Wistar-Kyoto rats: a behavioral and biochemical analysis.

Authors:  Joanna Jastrzębska; Małgorzata Frankowska; Łukasz Szumiec; Anna Sadakierska-Chudy; Anna Haduch; Irena Smaga; Beata Bystrowska; Wladyslawa A Daniel; Małgorzata Filip
Journal:  Behav Brain Res       Date:  2015-07-17       Impact factor: 3.332

7.  Age and sex differences in impulsive action in rats: the role of dopamine and glutamate.

Authors:  Christie L Burton; Paul J Fletcher
Journal:  Behav Brain Res       Date:  2012-02-01       Impact factor: 3.332

8.  Effects of GABAB receptor agonists on cocaine hyperlocomotor and sensitizing effects in rats.

Authors:  Małgorzata Frankowska; Ewa Nowak; Małgorzata Filip
Journal:  Pharmacol Rep       Date:  2009 Nov-Dec       Impact factor: 3.024

9.  Deficient response inhibition as a cognitive endophenotype of ADHD.

Authors:  Dorine Slaats-Willemse; Hanna Swaab-Barneveld; Leo de Sonneville; Emma van der Meulen; Jan Buitelaar
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-10       Impact factor: 8.829

10.  Pharmacokinetics of methylphenidate in man, rat and monkey.

Authors:  W Wargin; K Patrick; C Kilts; C T Gualtieri; K Ellington; R A Mueller; G Kraemer; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

View more
  9 in total

1.  Comparison of the VTA and LC response to methylphenidate: a concomitant behavioral and neuronal study of adolescent male rats.

Authors:  Tahseen J Karim; Cruz Reyes-Vazquez; Nachum Dafny
Journal:  J Neurophysiol       Date:  2017-06-14       Impact factor: 2.714

2.  Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.

Authors:  Britahny M Baskin; Bríd Á Nic Dhonnchadha; Linda P Dwoskin; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2017-07-20       Impact factor: 4.530

3.  Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD.

Authors:  Kathleen M Kantak; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2016-03-22       Impact factor: 3.533

4.  Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood.

Authors:  Chloe J Jordan; Carley Lemay; Linda P Dwoskin; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2016-09-06       Impact factor: 4.530

5.  Saikosaponin A Alleviates Symptoms of Attention Deficit Hyperactivity Disorder through Downregulation of DAT and Enhancing BDNF Expression in Spontaneous Hypertensive Rats.

Authors:  Sun Jichao; Han Xinmin; Ren Xianguo; Yin Dongqi; Zhou Rongyi; Lei Shuang; You Yue; Song Yuchen; Ying Jingnan
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-15       Impact factor: 2.629

6.  Ethanol Reinforcement Elicits Novel Response Inhibition Behavior in a Rat Model of Ethanol Dependence.

Authors:  Sucharita S Somkuwar; Leon W Quach; Jacqueline A Quigley; Dvijen C Purohit; McKenzie J Fannon; George F Koob; Chitra D Mandyam
Journal:  Brain Sci       Date:  2018-06-26

7.  Role of preexisting inhibitory control deficits vs. drug use history in mediating insensitivity to aversive consequences in a rat model of polysubstance use.

Authors:  Elon Mathieson; Carolyn Irving; Sarah Koberna; Megan Nicholson; Michael W Otto; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2022-04-07       Impact factor: 4.415

8.  Spontaneously Hypertensive Rat substrains show differences in model traits for addiction risk and cocaine self-administration: Implications for a novel rat reduced complexity cross.

Authors:  Kathleen M Kantak; Carissa Stots; Elon Mathieson; Camron D Bryant
Journal:  Behav Brain Res       Date:  2021-06-05       Impact factor: 3.352

9.  Behavioural effects of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis protocol.

Authors:  Douglas Teixeira Leffa; Alana Castro Panzenhagen; Diego Luiz Rovaris; Claiton Henrique Dotto Bau; Luis Augusto Rohde; Eugenio Horacio Grevet; Gabriel Natan Pires
Journal:  BMJ Open Sci       Date:  2018-10-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.